AP2006003537A0 - Use of polypeptides of the cupredoxin family in cancer therapy. - Google Patents

Use of polypeptides of the cupredoxin family in cancer therapy.

Info

Publication number
AP2006003537A0
AP2006003537A0 AP2006003537A AP2006003537A AP2006003537A0 AP 2006003537 A0 AP2006003537 A0 AP 2006003537A0 AP 2006003537 A AP2006003537 A AP 2006003537A AP 2006003537 A AP2006003537 A AP 2006003537A AP 2006003537 A0 AP2006003537 A0 AP 2006003537A0
Authority
AP
ARIPO
Prior art keywords
polypeptides
cancer therapy
cupredoxin family
cupredoxin
family
Prior art date
Application number
AP2006003537A
Other languages
English (en)
Inventor
Gupta Tapas T Das
Ananda M Chakrabarty
Yoshinori Hiraoka
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of AP2006003537A0 publication Critical patent/AP2006003537A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AP2006003537A 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy. AP2006003537A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
AP2006003537A0 true AP2006003537A0 (en) 2006-04-30

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003537A AP2006003537A0 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy.

Country Status (19)

Country Link
US (4) US7491394B2 (pt)
EP (2) EP1653990B1 (pt)
JP (1) JP2007502818A (pt)
KR (1) KR20060098358A (pt)
AP (1) AP2006003537A0 (pt)
AT (1) ATE470672T1 (pt)
AU (1) AU2004266632A1 (pt)
BR (1) BRPI0413574A (pt)
CA (1) CA2535581A1 (pt)
DE (1) DE602004027637D1 (pt)
EA (1) EA009897B1 (pt)
EC (1) ECSP066422A (pt)
GE (1) GEP20105022B (pt)
IL (1) IL173576A0 (pt)
NO (1) NO20061168L (pt)
NZ (1) NZ545355A (pt)
OA (1) OA13308A (pt)
TN (1) TNSN06059A1 (pt)
WO (1) WO2005018662A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1888106A4 (en) * 2005-05-20 2009-01-14 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH EPRININ SIGNALING USING CUPREDOXINS
KR20080019615A (ko) * 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
MX2007014599A (es) * 2005-05-20 2008-02-07 Univ Illinois Composiciones y metodos para el tratamiento de infeccion por vih con cupredoxina y citocromo c.
MX2008000993A (es) * 2005-07-19 2008-03-19 Univ Illinois Composiciones y metodos para controlar la angiogenesis con cupredoxinas.
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
BRPI0715027A2 (pt) 2006-09-11 2013-05-28 Univ Illinois modificaÇÕes dos peptÍdeos derivados da cupredoxina e seus mÉtodos de utilizaÇço
JP2010503409A (ja) * 2006-09-14 2010-02-04 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ クプレドキシンによって癌を予防する組成物および方法
MX2009005849A (es) * 2006-12-04 2009-08-12 Univ Illinois Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
KR20090114414A (ko) 2007-02-08 2009-11-03 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 암을 예방하는 조성물과 방법
AU2009294673B2 (en) * 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
US11136613B2 (en) 2015-04-30 2021-10-05 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DE69333814T2 (de) 1992-03-11 2006-02-02 Powderject Vaccines, Inc., Madison Genetischer impfstoff gegen den immunschwäche virus
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7084105B2 (en) 2001-02-15 2006-08-01 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
CN1863545A (zh) 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
MX2007014599A (es) 2005-05-20 2008-02-07 Univ Illinois Composiciones y metodos para el tratamiento de infeccion por vih con cupredoxina y citocromo c.
KR20080019615A (ko) 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Also Published As

Publication number Publication date
GEP20105022B (en) 2010-06-25
EP2263682A1 (en) 2010-12-22
US20080182782A1 (en) 2008-07-31
US20060292136A1 (en) 2006-12-28
US7888468B2 (en) 2011-02-15
EP1653990B1 (en) 2010-06-09
NZ545355A (en) 2009-10-30
DE602004027637D1 (de) 2010-07-22
AU2004266632A1 (en) 2005-03-03
WO2005018662A1 (en) 2005-03-03
EP1653990A1 (en) 2006-05-10
EA200600424A1 (ru) 2006-08-25
JP2007502818A (ja) 2007-02-15
US20140179617A1 (en) 2014-06-26
OA13308A (en) 2007-04-13
CA2535581A1 (en) 2005-03-03
NO20061168L (no) 2006-05-15
US7491394B2 (en) 2009-02-17
US10421801B2 (en) 2019-09-24
ECSP066422A (es) 2006-11-24
IL173576A0 (en) 2006-07-05
KR20060098358A (ko) 2006-09-18
TNSN06059A1 (en) 2007-10-03
US20060040269A1 (en) 2006-02-23
ATE470672T1 (de) 2010-06-15
EA009897B1 (ru) 2008-04-28
BRPI0413574A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
EP1482970A4 (en) ANTICANCER THERAPY
GB0307918D0 (en) Therapeutic use
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL175773A0 (en) Anti-igfr1 antibody therapeutic combinations
AU2003215460A8 (en) Cancer associated protein kinases and their uses
IL182624A0 (en) 2-amido-4 phenylthiazole derivatives, the preparation and the therapeutic use thereof
IL172316A0 (en) Novel compounds and their use in therapy
IL174047A0 (en) Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
ZA200210316B (en) Composition and its therapeutic use.
TWI368509B (en) Antituberculous therapeutic drugs and kit containing the same
ZA200709542B (en) Combination therapy in the treatment of cancer
AU2003255544A8 (en) Tumor specific oligosaccharide epitopes and use thereof
GB0326578D0 (en) Cancer diagnosis and therapy
AU2003227861A8 (en) Protein involved in cancer
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
SI1660532T1 (sl) Fuzijski polipeptidi in njihova uporaba pri antivaskularnem zdravljenju tumorjev
GB0226595D0 (en) Cancer therapy determination
IL171915A0 (en) Il-18 like polypeptides, their preparation and use
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
GB0303289D0 (en) Combination therapy
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors